ATTO Stock Forecast: Attovia Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$15
−3.08% on the day

The median 12-month analyst price target for Attovia Therapeutics, Inc. is $45. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 4 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$690.3M
Ticker Nerd rank
4/ 100
Median analyst target
$45
Analysts covering
5
Revenue$450K
Operating income−$21.8M
Net income−$20.7M
Free cash flow−$16.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.2%
1M
+7.5%
From high
−40.9%
From low
+10.0%
$14
$26
Range since 5 Aug 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Attovia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
4/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
49
Issuance
31
Revisions
23
Quality
16
Accruals
13
Growth
10
Momentum
2
Volatility
2

Value (49): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (2): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ATTO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATTO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 5 Aug 2026Adjusted close, US dollars
$10$20$30$40$50Sep 26Oct 26Nov 26ATTOHigh $52Median $45Low $34

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$34
Low
$45
Median
$52
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
10 Nov 2026CitigroupMaintainsBuy—
10 Nov 2026Morgan StanleyMaintainsOverweight—
31 Aug 2026CitigroupInitiatesBuy—
31 Aug 2026Leerink PartnersInitiatesOutperform—
31 Aug 2026LifeSci CapitalInitiatesOutperform—
31 Aug 2026Morgan StanleyInitiatesOverweight—
31 Aug 2026RBC CapitalInitiatesOutperform—
15 Aug 2022Barrington ResearchMaintainsOutperform$32 → $15
5 July 2022Goldman SachsMaintainsNeutral$28 → $14
21 Sept 2021Goldman SachsUpgradeNeutral$11 → $30
25 Nov 2020BairdMaintainsOutperform—
25 Nov 2020Bank of AmericaMaintainsNeutral—
25 Nov 2020Barrington ResearchInitiatesOutperform—
25 Nov 2020Credit SuisseDowngradeNeutral—
25 Nov 2020Goldman SachsDowngradeSell—
25 Nov 2020Morgan StanleyDowngradeEqual-Weight—
30 Apr 2020Goldman SachsDowngradeSell—
5 June 2019Morgan StanleyDowngradeEqual-Weight$8.00 → $3.00
8 Nov 2018BairdMaintainsOutperform$10 → $8.00
30 July 2018BairdMaintainsOutperform$12 → $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ATTO.

Market Radar

This page is one stock. Monday covers all of them.

ATTO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ATTO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

ATTO vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110Sep 26Oct 26Nov 26ATTOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ATTO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
479.3×

Cheaper than 1% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−36.7%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Attovia Therapeutics, Inc. has a market value of $690.3M and an enterprise value of $298.2M.

  • Shares outstanding: 43.0M.

  • Attovia Therapeutics, Inc. employs 50 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

ATTO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATTOAttovia Therapeutics, Inc.$690.3M4
LXRXLexicon Pharmaceuticals, Inc.$680.8M69
SLDBSolid Biosciences, Inc.$697.6M43
OABIOmniAb, Inc.$677.5M99
APMDApnimed, Inc.$669.7M4
AURAAura Biosciences, Inc.$710.3M61
NVCTNuvectis Pharma, Inc.$666.8M50

Take a look at ATTO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Attovia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ATTO

What is the ATTO stock price forecast for 2026-2027?

The median 12-month analyst price target for Attovia Therapeutics, Inc. is $45, with estimates ranging from $34 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATTO stock a buy right now?

Of the 5 analysts covering Attovia Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Attovia Therapeutics, Inc. 4 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATTO?

As at 21 Nov 2026, Attovia Therapeutics, Inc. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (49 of 100).

Will ATTO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $45, and Ticker Nerd's factor model ranks Attovia Therapeutics, Inc. 4 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATTO stock forecast for 2030?

No analyst covering Attovia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATTO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $52 over the next 12 months.

What does Attovia Therapeutics, Inc. do?

Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases. The company’s core work centers on its ATTOBODY platform, which is designed to create multispecific protein therapies that target multiple disease pathways involved in inflammation and immune dysfunction.

Company

About Attovia Therapeutics, Inc.

Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases. The company’s core work centers on its ATTOBODY platform, which is designed to create multispecific protein therapies that target multiple disease pathways involved in inflammation and immune dysfunction. Its current pipeline includes candidates for dermatology conditions such as atopic dermatitis and chronic pruritus, as well as gastroenterology and inflammatory disorders, including inflammatory bowel disease. Attovia Therapeutics Inc. develops therapeutic programs aimed at areas with significant unmet medical need, using a platform-based approach intended to improve specificity and broaden treatment options across several disease areas. The company is based in San Carlos, California.

CEO Mr. Tao Fu M.B.A., M.S. · 50 employees · United States · https://www.attovia.com